The SUSTAIN-6 trial for semaglutide (3,297 patients, median 2.1 years), LEADER trial for liraglutide (9,340 patients, median 3.8 years), and REWIND trial for dulaglutide (9,901 patients, median 5.4 years) all included comprehensive adverse event monitoring
AmelioICutruzzolFAntonovAAgostiniMMelinoG
For patients with Type 2 diabetes who also suffer from cardiovascular conditions, SGLT2 inhibitors are becoming an essential part of treatment plans
Similar content being viewed by others Introduction Globally, cardiometabolic diseases present a substantial health risk, positively correlating with most, if not all of the top CDC-listed causes of American death
Secure Packaging
PRP is derived from your own blood and contains concentrated platelets, growth factors, and other essential components for tissue repair and regeneration